Inactive Instrument

Press Releases NurExone Biologic Inc. Toronto S.E.

Equities

NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility	Apr. 25	AQ
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine	Apr. 22	AQ
NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine	Apr. 19	AQ
NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update	Apr. 02	AQ
Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise	Mar. 27	AQ
In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN	Mar. 22	AQ
NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence	Mar. 15	AQ
NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel	Mar. 08	AQ
NurExone Presenting Novel Regulatory Pathways for Exosomes Therapies at Global Summit	Mar. 01	AQ
NurExone’s Intellectual Property Portfolio Expands	Feb. 20	AQ
NurExone Launches Licensing Efforts for ExoTherapy Platform	Feb. 14	AQ

No results for this search